

High-affinity neoantigens correlate with better prognosis in antihepatocellular carcinoma (HCC) activity by activating CD39⁺CD8⁺ T cells

Gut

70, 1965-1977

DOI: [10.1136/gutjnl-2020-322196](https://doi.org/10.1136/gutjnl-2020-322196)

Citation Report

#	ARTICLE	IF	CITATIONS
1	The CD39+ HBV surface protein-targeted CAR-T and personalized tumor-reactive CD8+ T cells exhibit potent anti-HCC activity. <i>Molecular Therapy</i> , 2021, 29, 1794-1807.	3.7	37
2	An m6A-Related Prognostic Biomarker Associated With the Hepatocellular Carcinoma Immune Microenvironment. <i>Frontiers in Pharmacology</i> , 2021, 12, 707930.	1.6	12
3	HCC and Molecular Targeting Therapies: Back to the Future. <i>Biomedicines</i> , 2021, 9, 1345.	1.4	22
4	Limited Predictive or Prognostic Role of Tumor-Infiltrating Tissue-Resident Memory CD8 T Cells in Patients with Hepatocellular Carcinoma Receiving Immunotherapy. <i>Cancers</i> , 2021, 13, 5142.	1.7	2
5	Amplification of spatially isolated adenosine pathway by tumor-macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma. <i>Journal of Hematology and Oncology</i> , 2021, 14, 200.	6.9	68
6	Organoids as research models for hepatocellular carcinoma. <i>Experimental Cell Research</i> , 2022, 411, 112987.	1.2	7
7	ZCCHC17 Served as a Predictive Biomarker for Prognosis and Immunotherapy in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 799566.	1.3	2
9	Neoantigen Immunotherapeutic-Gel Combined with TIM-3 Blockade Effectively Restrains Orthotopic Hepatocellular Carcinoma Progression. <i>Nano Letters</i> , 2022, 22, 2048-2058.	4.5	17
10	Personalized neoantigen vaccine prevents postoperative recurrence in hepatocellular carcinoma patients with vascular invasion. <i>Molecular Cancer</i> , 2021, 20, 164.	7.9	44
11	Evaluation of the tumoricidal efficacy of adoptive cell transfer using hepatocellular carcinoma-derived organoids. <i>Journal of Gastrointestinal Oncology</i> , 2021, 13, 0-0.	0.6	2
12	Neoantigens as potential vaccines in hepatocellular carcinoma. , 2022, 10, e003978.		16
13	Multi-Level Analysis and Identification of Tumor Mutational Burden Genes across Cancer Types. <i>Genes</i> , 2022, 13, 365.	1.0	3
14	Black phosphorus-Au-thiosugar nanosheets mediated photothermal induced anti-tumor effect enhancement by promoting infiltration of NK cells in hepatocellular carcinoma. <i>Journal of Nanobiotechnology</i> , 2022, 20, 90.	4.2	19
15	Determining the Prognostic Value of Spliceosome-Related Genes in Hepatocellular Carcinoma Patients. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 759792.	1.6	4
16	Therapeutic Vaccines against Hepatocellular Carcinoma in the Immune Checkpoint Inhibitor Era: Time for Neoantigens?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2022.	1.8	13
17	LCK and CD3E Orchestrate the Tumor Microenvironment and Promote Immunotherapy Response and Survival of Muscle-Invasive Bladder Cancer Patients. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 748280.	1.8	7
18	Clinical and prognostic significance of CD14 (+) HLA-DR (low) myeloid-derived suppressor cells in patients with hepatocellular carcinoma received transarterial radioembolization with Yttrium-90. <i>Scandinavian Journal of Immunology</i> , 2022, 95, e13132.	1.3	4
19	Splenomegaly in predicting the survival of patients with advanced primary liver cancer treated with immune checkpoint inhibitors. <i>Cancer Medicine</i> , 2022, 11, 4880-4888.	1.3	9

#	ARTICLE	IF	CITATIONS
20	Hepatobiliary Tumor Organoids Reveal HLA Class I Neoantigen Landscape and Antitumoral Activity of Neoantigen Peptide Enhanced with Immune Checkpoint Inhibitors. <i>Advanced Science</i> , 2022, 9, .	5.6	17
21	Tertiary Lymphatic Structures in Primary Hepatic Carcinoma: Controversy Cannot Overshadow Hope. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
22	Patientâ€derived cancer organoids for drug screening: Basic technology and clinical application. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 1446-1454.	1.4	11
23	Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	58
24	Tumor-specific circRNA-derived antigen peptide identification for hepatobiliary tumors. <i>Engineering</i> , 2022, , .	3.2	1
25	NAPSB as a predictive marker for prognosis and therapy associated with an immuno-hot tumor microenvironment in hepatocellular carcinoma. <i>BMC Gastroenterology</i> , 2022, 22, .	0.8	3
26	A cohesinâ€associated gene score may predict immune checkpoint blockade in hepatocellular carcinoma. <i>FEBS Open Bio</i> , 0, , .	1.0	0
27	Integrative tumour mutation burden with CD39 and PD-L1 for the prediction of response to PD-L1 blockade and adjuvant chemotherapy in muscle-invasive bladder cancer patients. <i>British Journal of Cancer</i> , 2022, 127, 1718-1725.	2.9	1
28	Anti-PD-L1 antibody enhances curative effect of cryoablation via antibody-dependent cell-mediated cytotoxicity mediating PD-L1 ^{high} CD11b ⁺ cells elimination in hepatocellular carcinoma. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 632-647.	5.7	6
29	Integrated Analysis of Tumor Mutation Burden and Immune Infiltrates in Hepatocellular Carcinoma. <i>Diagnostics</i> , 2022, 12, 1918.	1.3	3
30	Complex in vitro 3D models of digestive system tumors to advance precision medicine and drug testing: Progress, challenges, and trends. , 2022, 239, 108276.		6
31	CDK2AP1 influences immune infiltrates and serves as a prognostic indicator for hepatocellular carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	2
32	Applications of human organoids in the personalized treatment for digestive diseases. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	7
33	Neoantigens and their clinical applications in human gastrointestinal cancers. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	0.8	1
34	Potential biomarkers: Identifying powerful tumor specific T cells in adoptive cellular therapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
35	Immune checkpoint inhibitor resistance in hepatocellular carcinoma. <i>Cancer Letters</i> , 2023, 555, 216038.	3.2	23
36	Clinical value of identifying genes that inhibit hepatocellular carcinomas. <i>Expert Review of Molecular Diagnostics</i> , 2022, 22, 1009-1035.	1.5	1
37	Interleukin-10 induces expression of CD39 on CD8 ⁺ T cells to potentiate anti-PD1 efficacy in EGFR-mutated non-small cell lung cancer. , 2022, 10, e005436.		3

#	ARTICLE	IF	CITATIONS
38	Variations in dynamic tumor-associated antigen-specific T cell responses correlate with HCC recurrence after thermal ablation. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
39	Pathogenesis to management of hepatocellular carcinoma. <i>Genes and Cancer</i> , 2022, 13, 72-87.	0.6	2
40	Tumour-infiltrating lymphocytes: from prognosis to treatment selection. <i>British Journal of Cancer</i> , 2023, 128, 451-458.	2.9	34
41	KRTCAP2 as an immunological and prognostic biomarker of hepatocellular carcinoma. <i>Colloids and Surfaces B: Biointerfaces</i> , 2023, 222, 113124.	2.5	3
42	A Systemic Inflammation Response Score for Prognostic Prediction in Hepatocellular Carcinoma Patients After Hepatectomy. <i>Journal of Inflammation Research</i> , 0, Volume 15, 6869-6881.	1.6	1
43	Organoids as an Enabler of Precision Immuno-Oncology. <i>Cells</i> , 2023, 12, 1165.	1.8	2
44	Tumor Mutational Burden for Predicting Prognosis and Therapy Outcome of Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3441.	1.8	13
45	TREM2+ macrophages suppress CD8+ T-cell infiltration after transarterial chemoembolisation in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2023, 79, 126-140.	1.8	17
46	Characterization of purinergic signaling in tumor-infiltrating lymphocytes from lower- and high-grade gliomas. <i>Purinergic Signalling</i> , 2024, 20, 47-64.	1.1	0
47	CD83 expression characterizes precursor exhausted T cell population. <i>Communications Biology</i> , 2023, 6, .	2.0	2
48	Machine learning integrations develop an antigen-presenting-cells and T-Cells-Infiltration derived LncRNA signature for improving clinical outcomes in hepatocellular carcinoma. <i>BMC Cancer</i> , 2023, 23, .	1.1	0
49	IL-12 and IL-27 Promote CD39 Expression on CD8+ T Cells and Differentially Regulate the CD39+CD8+ T Cell Phenotype. <i>Journal of Immunology</i> , 2023, 210, 1598-1606.	0.4	4
50	Dominant neoantigen verification in hepatocellular carcinoma by a single-plasmid system coexpressing patient HLA and antigen. , 2023, 11, e006334.		0
51	The Mutational, Prognostic, and Therapeutic Landscape of Neuroendocrine Neoplasms. <i>Oncologist</i> , 2023, 28, e723-e736.	1.9	3